European Journal of Medicinal Chemistry (2021)
Update date:2022-08-03
Topics: In vitro Testing Clinical Trials In Vivo Testing Combination Therapies Regulatory Approval
Tabti, Redouane
Lamoureux, Fran?ois
Charrier, Céline
Ory, Benjamin
Heymann, Dominique
Bentouhami, Embarek
Désaubry, Laurent
Current therapeutic approaches to osteoporosis display some potential adverse effects and a limited efficacy on non-vertebral fracture reduction. Some sulfonylamidines targeting the scaffold proteins prohibitins-1 and 2 (PHB1/2) have been showed to inhibit the formation of osteoclasts in charge of bone resorption. Herein, we report the development of a second generation of anti-osteoclastic PHB ligands. The most potent compound, IN45, showed 88% inhibition at the low concentration of 5 μM, indicates that it might serve as a basis for the development of new antiosteoporotic drugs.
View MoreContact:86-379-63338609
Address:Jiudian Village,Deting Town,Song County,Luoyang
Shanghai Egoal Chemical Co.,Ltd
Contact:+86-21-50333091
Address:Yangming Garden Square 3,YangGao North Road 1188, Pudong New District, Shanghai
Nanjing Vincero International Trading Co.,Ltd
Contact:8618936897229
Address:NO.68, ZhuShan Road, JiangNing WanDa Plaza, Building E Room 1703
Shandong Jusage Technology Co.,Ltd.
Contact:86-13406130167
Address:No.20,North Ride No.9 Road, Guangrao Economic Development Zone, Shandong Province
Yancheng Creator Chemical Co., Ltd
Contact:0086-515-88710008 88710068 88710858 88710868
Address:No.21 Renming Road, Longgang Town, Yandu County,Yancheng City
Doi:10.1039/c5cc00430f
(2015)Doi:10.1021/jo971391b
(1997)Doi:10.1055/s-1997-986
(1997)Doi:10.1039/a705052f
(1997)Doi:10.1016/j.molliq.2021.115842
(2021)Doi:10.1016/j.bmc.2018.06.024
(2018)